Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
leucovorin + oxaliplatin + tegafur-uracil
- Development stage
- Unknown
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination chemotherapy regimen consisting of leucovorin (folinic acid), oxaliplatin, and tegafur-uracil (UFT). Tegafur is a prodrug of 5-fluorouracil (5-FU) that is converted in the liver to active 5-FU, which inhibits thymidylate synthase and disrupts DNA synthesis. Uracil acts as a competitive inhibitor of dihydropyrimidine dehydrogenase, increasing the bioavailability and efficacy of 5-FU. Leucovorin enhances the binding of 5-FU to thymidylate synthase, further potentiating its antitumor effect. Oxaliplatin is a platinum-based chemotherapeutic agent that forms DNA crosslinks, inhibiting DNA replication and transcription. This combination is primarily used as adjuvant or palliative therapy for colorectal cancer[1][2].
- Other names
- UFT/LV + oxaliplatinUFT/leucovorin/oxaliplatintegafur/uracil/leucovorin/oxaliplatin
02
Targets
TS (Thymidylate synthase)DNADPYD (Dihydropyrimidine dehydrogenase)
Beyond the preview
Go deeper on leucovorin + oxaliplatin + tegafur-uracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on leucovorin + oxaliplatin + tegafur-uracil.